These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 24753221)

  • 41. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
    Buhlinger KM; Fuller KA; Faircloth CB; Wallace JR
    Am J Health Syst Pharm; 2019 Aug; 76(16):1204-1210. PubMed ID: 31369115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
    Miano TA; Hennessy S; Yang W; Dunn TG; Weisman AR; Oniyide O; Agyekum RS; Turner AP; Ittner CAG; Anderson BJ; Wilson FP; Townsend R; Reilly JP; Giannini HM; Cosgriff CV; Jones TK; Meyer NJ; Shashaty MGS
    Intensive Care Med; 2022 Sep; 48(9):1144-1155. PubMed ID: 35833959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime.
    Quach HT; Esbenshade AJ; Zhao Z; Banerjee R
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27750. PubMed ID: 30989780
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vancomycin With Concomitant Piperacillin/Tazobactam vs. Cefepime or Meropenem Associated Acute Kidney Injury in General Ward Patients: A Multicenter Propensity Score-Matched Study.
    Komerdelj IA; Buckley MS; D'Alessio PA; Ziadat DS; Kobic E; Rangan P; Agarwal SK; Tinta NC; Yerondopoulos MJ; Kane-Gill SL
    J Pharm Pract; 2024 Feb; 37(1):80-87. PubMed ID: 36075000
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
    Rungkitwattanakul D; Ives AL; Harriott NG; Pan-Chen S; Duong L
    J Chemother; 2022 Apr; 34(2):103-109. PubMed ID: 34424136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.
    Lee JD; Heintz BH; Mosher HJ; Livorsi DJ; Egge JA; Lund BC
    Clin Infect Dis; 2021 Oct; 73(7):e1579-e1586. PubMed ID: 33382398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The concomitant use of vancomycin and piperacillin-tazobactam is associated with acute kidney injury (AKI) in extremely low birth weight infants (ELBW).
    Al-Jebawi Y; Karalic K; Shekhawat P; Mhanna MJ
    J Neonatal Perinatal Med; 2022; 15(2):303-309. PubMed ID: 34864693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Nephrotoxicity of Vancomycin.
    Filippone EJ; Kraft WK; Farber JL
    Clin Pharmacol Ther; 2017 Sep; 102(3):459-469. PubMed ID: 28474732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.
    Blevins AM; Lashinsky JN; McCammon C; Kollef M; Micek S; Juang P
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study.
    Yamashita Y; Kawaguchi H; Yano T; Sakurai N; Shibata W; Oshima K; Imai T; Yamada K; Nakamura Y; Nagayama K; Kakeya H
    J Infect Chemother; 2021 Nov; 27(11):1614-1620. PubMed ID: 34366231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study.
    O'Callaghan K; Hay K; Lavana J; McNamara JF
    Int J Antimicrob Agents; 2020 Jul; 56(1):106010. PubMed ID: 32413387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study.
    Okada N; Izumi Y; Nakamoto A; Chuma M; Goda M; Yagi K; Aizawa F; Hamano H; Zamami Y; Azuma M; Ishizawa K
    Clin Ther; 2021 Nov; 43(11):1910-1920.e3. PubMed ID: 34642081
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A retrospective cohort study assessing acute kidney injury and renal recovery among septic patients empirically treated with vancomycin piperacillin-tazobactam versus vancomycin cefepime.
    Elliott BP; Tang MM; Madden JA; Markert RJ; Burdette SD; Pleiman CM; Speelmon EC
    Intern Emerg Med; 2022 Jan; 17(1):91-99. PubMed ID: 34089468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin.
    Rutter WC; Burgess DS
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712661
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin.
    Schreier DJ; Kashani KB; Sakhuja A; Mara KC; Tootooni MS; Personett HA; Nelson S; Rule AD; Steckelberg JM; Tande AJ; Barreto EF
    Clin Infect Dis; 2019 Apr; 68(9):1456-1462. PubMed ID: 30165426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime.
    Molina KC; Barletta JF; Hall ST; Yazdani C; Huang V
    J Intensive Care Med; 2020 Dec; 35(12):1434-1438. PubMed ID: 30741072
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short Versus Extended Duration Vancomycin and Piperacillin/Tazobactam and the Incidence of Acute Kidney Injury in Noncritically Ill Patients.
    Traversa A; Hammond DA; Peksa GD; DeMott JM
    J Pharm Pract; 2021 Dec; 34(6):882-887. PubMed ID: 32578474
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk and Time-to-Onset of Acute Kidney Injury With Vancomycin Plus Piperacillin-tazobactam Combination: Analysis Using JADER.
    Ide N; Sako KI; Takigawa M; Tanaka H
    In Vivo; 2024; 38(3):1436-1442. PubMed ID: 38688650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do?
    Watkins RR; Deresinski S
    Clin Infect Dis; 2017 Nov; 65(12):2137-2143. PubMed ID: 29020249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.